

Supplementary Materials

Table S1. Comparisons of dose parameters according to sigmoid circumference

Sigmoid circumference (%)		EQD ₂ (Gy)						
		GTV D _{98%}	HR-CTV D _{98%}	IR-CTV D _{98%}	Rectum D _{2mL}	Sigmoid D _{2mL}	Bladder D _{2mL}	Bowel D _{2mL}
0 (n = 11)	2D	139.4 ± 42.9	80.7 ± 14.4	63.8 ± 7.0	65.3 ± 7.7	56.4 ± 3.8	87.8 ± 17.7	66.5 ± 15.0
	3D	118.0 ± 27.1	73.6 ± 10.7	60.7 ± 4.6	65.6 ± 8.8	56.2 ± 7.7	79.7 ± 7.6	57.9 ± 6.8
0–10 (n = 26)	2D	142.0 ± 55.5	83.7 ± 11.0	66.5 ± 7.9	62.6 ± 7.7	66.9 ± 7.0	88.7 ± 18.3	59.9 ± 13.3
	3D	119.0 ± 36.1	80.8 ± 7.2	64.8 ± 4.8	62.2 ± 6.2	65.9 ± 7.1	81.6 ± 9.4	55.7 ± 6.1
>10 (n = 13)	2D	120.4 ± 56.2	81.2 ± 13.6	65.3 ± 8.5	57.1 ± 6.3	76.1 ± 11.1	87.4 ± 10.4	52.7 ± 9.5
	3D	116.9 ± 45.4	82.6 ± 4.1	66.3 ± 3.5	57.3 ± 5.1	71.0 ± 5.7	81.9 ± 5.3	51.3 ± 7.8

Values are presented as mean ± standard deviation.

Bold type was statistically significant factor.

EQD₂, 2 Gy equivalent dose; GTV, gross tumor volume; HR-CTV, high-risk clinical target volume; IR-CTV, intermediate-risk clinical target volume; 2D, two-dimensional; 3D, three-dimensional.